Tuesday, Apr 24, 2018 8:00a -
Thursday, Apr 26, 2018 5:00p
The Aloft Boston Seaport
401-403 D St
Boston, MA 02210
As the first generation of antigen-specific immune tolerance therapies enter clinics and with excitement around recent partnerships, IPOs and investments reaching new heights, now is the time for an industry forum for large pharma, pioneering biotech and academia to be able to meet and share knowledge.
The 1st Antigen-Specific Immune Tolerance Drug Development Summit is that forum, and has a brand-new agenda that can help you successfully overcome the scientific, product development and commercialization challenges currently being faced.
Conference + 2 Workshops Earlybird (Book by 26/01/18): USD 3197
Conference + 2 Workshops (standard rate): USD 3797
Conference + 1 Workshop Earlybird (Book by 26/01/18): USD 2798
Conference + 1 Workshop (standard rate): USD 3398
Conference Earlybird (Book by 26/01/18): USD 2199
Conference (Standard rate): USD 2799
Speakers: Amy S. Rosenberg (CDER/FDA), Arpita Maiti (Pfizer, Inc.), Lachy McLean (Takeda Pharmaceuticals), Jose M. Carballido (Novartis), Jack A. Ragheb (Eli Lilly & Co), Lawrence A. Steinman (Tolerion), Laurence A. Turka (Immune Tolerance Network), Matthias von Herrath (Novo Nordisk), Kei Kishimoto (Selecta Biosciences), Jonathan Zalevsky (Nektar Therapeutics), Francisco J. Quintana (AnTolRx)
Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development